Rheumatoid Arthritis DMARD Intervention and UtilizationStudy

To systematically collect and document use patterns, effectiveness and safety of DMARD treatments currently used in the management of rheumatoid arthritis. The primary purpose of this study is to estimate the incidence of serious adverse experiences and adverse experiences of interest in patients with rheumatoid arthritis (RA) treated with ENBREL®.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rheumatoid Arthritis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Fulfillment of the 1987 American Rheumatism Association criteria for RA
Currently requiring the addition of ENBREL® therapy (to be taken alone or in addition to their current DMARD therapy)

Exclusion criteria

Currently or previously enrolled in RADIUS 1
Currently enrolled in a clinical trial where treatments or patient visits are imposed by a protocol
Active infections
Known allergy to ENBREL® or any of its components
Current treatment with ENBREL®
Patients who have previously been demonstrated to be intolerant of or refractory to ENBREL® therapy
Nursing or pregnant women

Treatment and study plan

Enbrel®

Drug

50 mg/wk SC

Sponsors and collaborators

Lead sponsor

Amgen

Industry

Collaborators

Immunex Corporation
Wyeth is now a wholly owned subsidiary of Pfizer

Registry information

Official study title

Rheumatoid Arthritis Disease Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study (RADIUS 2)

Important dates

Study start: 2002
Primary completion: 2008
Study completion: 2008
First posted: Jul 1, 2005
Registry last updated: May 6, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed